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Background: Disturbances of Ca2+ homeostasis underlie several cardiovascular 
diseases such as heart failure, myocardial infarction, and hypertension. One form of 
Ca2+-dependent myocardial injury that occurs in hearts exposed to hypocalcaemia is 
the Ca2+ paradox (CP) phenomenon. Several factors have been proposed to modulate 
the degree of CP-induced injury including disturbances in other electrolytes such as 
magnesium (Mg2+). However, the role of Mg2+ or the Mg2+-sensitive, Ca2+-permeable 
channels called transient receptor potential (TRP) melastatin 7 (TRPM7) channels in 
CP is not known. 
Aims: The aim of this study was to investigate the effects of Mg2+ pretreatment and 
of pharmacological inhibitors of TRPM7 channels on CP-induced cardiac injury in 
the isolated rat heart. 
Methods: A total of 84 adult male Wistar rats were used in this study, including 
those in preliminary experiments to optimize in-vivo treatments and ex-vivo cardiac 
perfusion protocols. In experiments to test the effect of Mg2+ pretreatment on CP, rats 
were injected with MgSO4 (270 mg/kg body weight, i.p) once per day for seven 
consecutive days. Control rats received equivalent volumes of saline. In experiments 
to test the effects of Mg2+ sensitive ion channels inhibitors, fingolimod (FTY720) 
and nordihydroguaiaretic acid (NDGA), rats were not pretreated with MgSO4. On the 
day of experiments, hearts were extracted under anaesthesia and perfused on a 
constant-pressure Langendorff system. CP was elicited by perfusing hearts with 
Ca2+-free Krebs-Henseleit (K-H) solution for 3 min followed by 30 min of Ca2+-
containing solution. Control hearts were perfused with ordinary K–H solution. 
FTY720 (1 µmol/l) or NDGA (10 µmol/l) was applied for 5 min before CP. 
Haemodynamic parameters such as left ventricular developed pressure (LVDP) and 
LV end diastolic pressure (LVEDP) were recorded using an intraventricular balloon. 
Coronary flow rate (CFR) was assessed by timed coronary effluent collection. 
Oxygen saturation in K-H was measured with a dissolved O2 meter and used to 





triphenyltetrazolium chloride staining. Plasma Mg2+ levels were measured using an 
automated photometric assay.  
Results: CP caused a dramatic impairment in cardiac performance as was reflected 
by a marked increase  of baseline non-viable myocardial tissue from 7.0 ± 0.5 % in 
controls to infarct size of 50.0 ± 3.0 % (mean ± SEM, p = 0.0001 vs control,), a 
decrease in LVDP from a value of 72 ± 11 mmHg in control to almost nil in CP 
(p = 0.001 vs control), and an increase in LVEDP from 16 ± 3 mmHg in control to 
41 ± 11 mmHg (p = 0.03 vs control). CP also significantly decreased MVO2 from 
202 ± 19 mg/min in control to 99 ± 17 mg/min (p = 0.01 vs control), but without 
statistically significant effects on CFR. Mg2+ pretreatment did not alter the 
CP-induced changes in infarct size, LVDP, LVEDP, MVO2, or CFR (p > 0.05, 
CP + Mg2+ vs CP). Plasma ionised Mg2+ levels in Mg2+ pretreated hearts were not 
significantly different compared to those in control rats (p > 0.05). Compared to 
hearts exposed to CP alone, FTY720, but not NDGA, reduced the infarct size to 
36 ± 5% (p < 0.001vs CP), improved post CP LVDP to 51 ± 15 mmHg (p < 0.05, 
FTY + CP vs CP) and decreased  post CP LVEDP to 45 ± 7 mmHg (p < 0.01, 
FTY + CP vs CP). FTY720 did not significantly alter MVO2 or CFR during CP. 
Conclusion & discussion: These results showed that FTY720 application, but 
not NDGA application or Mg2+ pretreatment, partially reversed the CP-induced 
injury as was indicated by a decrease in infarct size and improvement of 
haemodynamic function, but without effect on CFR. The mechanisms underlying the 
FTY720 cardioprotection seem to be unrelated to its modulation of TRPM7 
channels, given the lack of protection by both Mg2+ pretreatment and NDGA. The 
results suggest that there is a potential for the clinical uses of FTY720 to be extended 
to provide cardioprotection in conditions of CP. However, it is still not clear if the 
sphingosine 1-phosphate receptor-mediated mechanisms that are common to the 
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Cardiovascular diseases  
According to the recent World Health Organization 2015 report (WHO, 2015), 
cardiovascular diseases (CVDs) are the number one cause of death and disability 
worldwide. In addition, 17.5 million people died from CVDs in 2012, representing 
31% of all global deaths (WHO, 2015). Furthermore, CVDs have a higher mortality 
in developing countries than in developed ones,  which contribute about 80% of 
global CVD-related deaths and 87% of CVD-related disabilities (Boutayeb and 
Boutayeb 2005; Callow 2006). The possible reason for the high incidences and 
prevalence of CVDs in developing countries is that there has been an increase in 
urbanization and changing lifestyles in the past few decades (Akinboboye, Idris, and 
Akinkugbe 2003). This is likely to be the case in countries such as South Africa 
where CVDs are the second most common cause of death in adults above the age of 
65 years (Mayosi et al. 2009). In addition, CVDs impose a great health economic 
burden on societies around the world, with the USA spending a huge budget of more 
than $400 billion on CVDs in 2006 (Mensah and Brown 2007). Given that over 80% 
of CVD-related deaths occur in low- and middle income countries (WHO, 2015); the 
health-economic burden implications are greater in these countries. It is therefore 
important to understand the pathophysiology of CVDs in order to find ways to 
improve their prevention and treatment.  
 
A major underlying pathological feature of most of CVDs is a disturbance of calcium 
(Ca2+) homeostasis (Gwathmey et al. 1987). Ca2+ dysregulation is associated with 
cytoplasmic Ca2+ overload, which induces cardiovascular tissue degenerative 
changes, metabolic disturbances, electrical dysfunction, and cytotoxicity. Therefore, 
cellular processes that regulate cytoplasmic Ca2+ represent potential therapeutic 








 homeostasis  
Ca2+ is one of the important mediators required for normal cell structural- and 
functional maintenance in the heart (Carafoli 1985), hence its cytoplasmic 
homeostasis is vital. Under resting status, Ca2+ concentration in the cytoplasm is 
normally maintained in the nanomolar range, whereas extracellular and sarcoplasmic 
reticulum (SR) Ca2+ concentrations are in millimolar range (Beuckelmann and Wier 
1988). In cardiac cells, cytoplasmic Ca2+ homeostasis results from the integrated 
function of trans-sarcolemmal Ca2+ influx and efflux pathways as well as Ca2+ influx 
and efflux from intracellular organelles such as sarcoplasmic reticulum (SR) 
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VGCC (Voltage gated Ca2+channels), TRPs (Transient receptor potential  channels), SOCs (Store-
operated channels), NCXs  (Na+/Ca2+ exchangers), PMCA (sarcolemmal Ca2+ ATPase), SERCA 
(Sarcoplasmic reticulum Ca2+- ATPase) and RYR ( Ryanodine receptors). The arrows point to the 






Sarcolemmal Ca2+ influx occurs through channels that can be classified on the basis 
of their regulatory mechanisms such as voltage-operated, receptor-operated (ROCs) 
and store-operated channels (SOCs). Voltage-gated Ca2+ channels include L-type 
Ca2+  channel and T-type Ca2+  channels (Hagiwara and Kameyama 1988). The L-
type Ca2+  channels are mainly expressed in the transverse tubules, and are activated 
by potentials ≥- 40 mV and  inactivated by increase level of intracellular Ca2+ (Lee et 
al. 1999). T-type Ca2+  channels are mainly expressed in atrial pacemaker cells and 
Purkinje fibres (Mitra and Morad 1986), and are activated by potentials ≥-65 mV and 
inactivated during early depolarization (Vassort, Talavera, and Alvarez 2006). 
 
Storeoperated Ca2+ channels (SOCs) have been reported in neonatal cardiac 
myocytes, but are generally thought to be absent in adult cardiac cells (Uehara et al. 
2002). These channels are regulated by the state of filling of the intracellular 
organelle stores with Ca2+ through a mechanism known as capacitative Ca2+ entry. 
When the intracellular stores are full with Ca2+, there is no Ca2+ entry into the cell, 
but as soon as the stores are depleted, extracellular Ca2+ enters  across the plasma 
membrane via SOCs (Parekh, Fleig, and Penner 1997). 
 
Transient receptor potential (TRP) channels are molecular members of cation 
permeable channels that are expressed in cardiac and other tissues (Birnbaumer et al. 
1996). Several of these non-selective channels are Ca2+ permeable and are regulated 
by different stimuli, such as voltage, temperature and ligand binding (Voets et al. 
2004). TRP channels may therefore contribute to cytoplasmic Ca2+ entry in response 
to various physiological and pathological stimuli. In addition, some TRP channels 
such as TRPC3are also proposed to act as SOC channels (Montell et al. 2002). 
There are also several other Ca2+-permeable channels that are activated by ligand-
binding and physical stimuli, for which the molecular identities are not well-known. 
These channels include insulin-sensitive monovalent cation channels (Zhang & 
Hancox 2003), stretch-activated cation channels (Zhang et al. 2000), and swelling-





between these various non-selective cation channels and their role in regulating 
cytoplasmic Ca2+ remain unclear. 
 
Sarcolemmal Ca2+ efflux occurs through pumps that are located on the plasma 
membrane, including Na+/Ca2+ exchanger (NCX) (Wanaverbecq, Marsh, and Brown 
2003). The exchanger takes a mutually exclusive manner of action to bind either one 
Ca2+ ion to move it out of the cell and three Na+ ions to move them into the cell. 
Under normal conditions, cytosolic Ca2+ and ATP serve as activators of this 
exchanger, while high levels of cytosolic Na+ act as an inhibitor (Hilgemann et al. 
1992). The  activity of NCX depends upon the electrochemical ion gradients and its 
direction of action is fully reversible (Hilgemann et al. 1992). Activation of NCX in 
reverse mode therefore leads to Ca2+ overload (Barry and Bridge 1993). 
 
There are also Ca2+ channels and pumps located on the SR membrane that regulate 
cytoplasmic Ca2+, and these include ryanodine receptors and the sarcoplasmic 
reticulum Ca2+-ATPase (SERCA). The ryanodine receptors act as SR Ca2+ efflux 
channels and are responsible for Ca2+ release from the SR in response to Ca2+ 
binding.  Ryanodine receptors are activated by sarcolemmal influx of Ca2+ via the  L-
type channel in response to action potential depolarisation (Mochizuki and Jiang, 
1998). Ryanodine receptor opening increases cytosolic Ca2+, which activates Ca2+ 
sensitive contractile proteins (e.g., troponin C) and trigger cardiac muscle contraction 
(Cheng, Lederer, and Cannell 1993). The Ca2+ released from the SR is eventually 
taken back up into the SR via SERCA. The regulation of SERCA occurs by 
phosphorylation of phospholamban, a protein that inhibits Ca2+ transport by SERCA 




 abnormalities and CVDs 
 
Abnormal cytoplasmic Ca2+ concentration can lead to cardiac mechanical 
dysfunction. Elevated cytoplasmic Ca2+ activates myofilaments to produce cardiac 
hypercontraction (systolic dysfunction), whereas defects of Ca2+ removal hamper 





1987). In failing hearts, aberrant excitation-contraction coupling occur due to 
disruptions in cytoplasmic Na+ and Ca2+  homeostasis and prolonged Ca2+ transient 
which leads to electrical instability. These changes are compounded by decrease of 
Ca2+ reuptake into the SR (Monte et al. 2004). 
 
Pathological cardiac hypertrophy can be induced by abnormalities in Ca2+-dependent 
pathways. The major Ca2+-dependent hypertrophic signaling pathways are Ca-
calmodulin-histone deacetylase and Ca-calcineurin-nuclear factor of activated T cells 
(Mitra and Morad 1986). Activation of calcineurin causes dephosphorylation of the 
nuclear factor of activated T cells (NFAT) that activates some gene transcription. 
Ca2+-induced hypertrophy is associated with marked changes in myocardial 
contractility, an increase in peak active tension and slowing of the rates of tension 
development and relaxation (Gwathmey et al. 1987).  
 
In vascular diseases, changes of intracellular Ca2+ handling are implicated in the 
pathophysiology of hypertension. Increased cytosolic Ca2+ concentration in both 
platelets and smooth muscle cause an increase in total peripheral vascular resistance 
(McCarron 1985). In coronary vascular atherosclerosis, there is an increase of aortic 
smooth muscle cell membrane Ca2+ permeability. The resulting increase in 
intracellular Ca2+ is suggested to play a causal role in atherogenesis by initiating or 
accelerating Ca2+-dependent intracellular processes that induce damage (Strickberger 
et al. 1988). 
 
Ca2+ itself as a cation, is also directly involved in myocardial ischaemic injury and 
cell death through Ca2+-mediated cytotoxicity (Steenbergen et al. 1987). A defect in 
the myocardial Ca2+ transport system with cytosolic Ca2+   overload is a major 
contributor to myocardial ischaemia/reperfusion (I/R) injury as seen in some 
cardiovascular treatment procedures and ischaemic heart disease. During ischaemia, 
excess uptake of Ca2+ into the cytosol induces mitochondrial Ca2+ overload and 
impairments of ATP generation (Frank et al. 1982). Furthermore, Ca2+ abnormalities 
participate in mitochondrial damage after activation of Ca2+-dependent proteases and 





the cell membranes and depression of the mitochondrial oxidative phosphorylation 
(Jin et al. 2005; Ferrari 1996). 
 Another key form of Ca2+-mediated myocardial injury that is induced directly by 
changes in Ca2+ even in the absence of ischaemia is a phenomenon called Ca2+ 
paradox. During this phenomenon, the myocardial damage is due to the temporary 
removal and replacement of the extracellular Ca2+ (Zimmerrman and Hulsmann 
1966; Alto and Dhalla 1981). Clinically, Ca2+ paradox-induced myocardial injury is 
associated with the use of low-Ca2+ concentration solutions such as cardioplegic 




 paradox-induced cardiac injury  
The term Ca2+ paradox was first used by Zimmerman and Hulsmann (1966) to 
describe a series of observations resulting from the reintroduction of Ca2+ (Ca2+ 
repletion) to an isolated rat heart previously perfused with a medium free of Ca2+ 
(Ca2+ depletion). Ca2+ depletion and repletion are associated with marked and 
irreversible loss of contractile function, loss of intracellular proteins and massive 
ultrastructural damage. Ca2+ paradox has been studied in the heart of various 
mammalian species such as rats, dogs, cats, rabbits, guinea pigs and mice as well as 
in isolated cardiomyocytes in rats and mice. As a result, Ca2+ paradox has become an 
important experimental model for studying the morphological, electrophysiological 
and biochemical basis of myocardial injury associated with Ca2+ abnormalities. The 
phenomenon therefore has stimulated interest among researchers in exploring the 
possible underlying mechanisms and in finding ways to prevent it.  
 
Mechanisms of the Ca2+ paradox phenomenon 
Although the exact mechanisms leading to the Ca2+ paradox damage remain to be 
elucidated, various events have been proposed to occur during Ca2+ depletion  and 
Ca2+  repletion, which include electrical- and mechanical changes, morphological 






Mechanical, morphological and electrical changes: 
Ca2+ paradox appears to be caused by dramatic mechanical, morphological and 
electrical changes. During Ca2+ depletion, separation between the surface coat and 
external lamina of the glycocalyx covering sarcolemmal surface can occur (Ashraf 
1979; Frank et al. 1982). Intercalated discs are separated at adherent site of maculae 
and fasciae junctions, while other cell-cell contacts remain structurally intact (Ashraf 
1979). During Ca2+ repletion, contractile force may induce breaks in both plasma 
membrane and basal lamina as well as tears in the lipid bilayer and further damage of 
glycocalyx (Ashraf 1979; Frank et al. 1982). The developed force in cardiomyocytes 
is only transmitted to the areas where adjacent cells remain intact and this creates 
excessive and uneven mechanical tension leading to sarcolemmal disruption. For this 
reason, Singal et al., (1979) reported that during Ca2+ depletion the ultrastructural 
changes are minimal and become clear after Ca2+ repletion when contraction occurs.  
 
During Ca2+ depletion, the generation of electrical activity remains normal, although 
there is a rapid cessation of contractile activity (electromechanical dissociation) 
(Holland and Olson 1975; Hearse, Humphrey, and Bullock 1978). During Ca2+ 
repletion, the electrical activity disappears and therefore the contractile activity is not 
restored (Holland and Olson 1975). These events lead to failure of cellular 
depolarization and the development of action potentials, conduction abnormalities 
and ventricular arrhythmias (Holland and Olson 1975). 
 
Ca2+ overload:  
Cytosolic Ca2+ overload is considered to be the hallmark of Ca2+ paradox-induced 
injury and is believed to be due to an alteration in the ability of the myocardium to 
regulate the level of cytoplasmic Ca2+ (Ruigrok and Nether, 1985). Ca2+ overload 
causes excessive contractile activation and hypercontracture. Cytosolic Ca2+ overload 
can result from Ca2+ influx across the sarcolemma, e.g., via Ca2+ permeable channels 
or the NCX working in the reverse mode. It may also be due to the  release of Ca2+ 
from endogenous stores or depressed SR Ca2+ uptake by SERCA (Tamura et al. 





Ca2+-permeable channels such as TRP channels become permeable to Na+ and that 
leads to a cellular Na+ overload, which activates the reverse mode of NCX leading to 
Ca2+ overload (Nayler et al. 1984). The activity of the NCX during Ca2+ paradox is 
proposed to be biphasic (Makino et al.1988); it is stimulated during early period of 
reperfusion, but gets depressed during the latter stages. It was suggested that the 
early stimulation may represent an adaptive mechanism due to the reperfusion ion-
induced influx of Ca2+, whereas the delayed depression may contribute further to 
cytoplasmic Ca2+ overload. Furthermore, Ca2+ overload can be mediated by Ca2+ 
entry through some Ca2+-permeable transient receptor potential protein (TRP) 
channels. Kojima et al. (2010) reported that the Ca2+ paradox is primarily mediated 
by Ca2+ entry through TRPCs that are presumably activated by SR Ca2+ depletion.  
 
Biochemical changes: 
Ca2+ paradox also leads to some biochemical changes in cardiomyocytes, including a 
decrease in high energy phosphates, acidification of the cytoplasm and activation of 
hydrolytic enzymes. Excessive gain of Ca2+ leads to a massive loss of myoglobin and 
cytosolic enzymes (creatine kinase and pyruvate kinase) (Hearse et al. 1978; Ruigrok 
and Nether 1985). In addition, in the early phase of Ca2+ repletion there is a  sudden 
and severe decline of myocardial contents of high energy phosphates and an increase 
in creatine, ADP and AMP (Hearse et al. 1978; Nayler 1980). The main cause of 
exhaustion of creatine phosphate and ATP are an excessive breakdown of ATP by 
Ca2+-activated ATPase and an impaired phosphorylating capacity of the 
mitochondria. Both the hydrolysis of ATP and excessive Ca2+ uptake of 
mitochondria are accompanied by the release of H+ ions, which may acidify the 
cytoplasm triggering the destructive action of Ca2+- and H+-dependent phospholipase 
and proteases in the cytoplasm and the lysosomes (Lamers, Stinis, and Ruigrok 
1984). Some Ca2+-activated proteases such as calpains are absolutely dependent on 
Ca2+ for their catalytic activities and are proposed to induce Ca2+ paradox (Tong et 
al. 2012). Ca2+ repletion significantly increases the calpain-mediated proteolysis and 
the translocation of both μ- and m-calpain to the sarcolemmal membrane. Both μ- 





results in the hydrolysis of many structural and functional proteins, consequently 
leading to cell death and cardiac dysfunction (Bi et al. 2012; Tong et al. 2012).  
 
Factors affecting Ca2+ paradox-induced cardiac injury 
Several factors have been proposed to modulate the degree of Ca2+ paradox-induced 
injury, including the duration of exposure to Ca2+ depletion (Ashraf 1979), perfusate 
pH (Bielecki 1969) and temperature (Rich and Langer 1982), other electrolyte 
disturbances and some of pharmacological agents.  
 
Duration of exposure to Ca2+ depletion:  
Ca2+ paradox-induced myocardial injury may be affected by the duration of Ca2+ 
depletion which is determined by the length of time that the heart is perfused with 
Ca2+-free solution (Rich and Langer 1982; Gaintanaki et al. 2002) In order to induce 
the Ca2+ paradox phenomenon, the Ca2+ free period must last anywhere from 2-40 
minutes depending on the species and tissue being employed. In isolated perfused rat 
hearts,  perfusion with Ca2+-free solution for 3-5 minutes been found to be sufficient 
to induce injury, indicating that some structural and/or functional changes are 
introduced in the myocardial cell (Tong et al. 2012; J. Zhang et al. 2012). The 
apparent gross structural damage of myocardium due to Ca2+ depletion has only been 
observed after a prolonged exposure to the Ca2+-free medium. Longer duration of 
exposure to Ca2+ depletion has been associated with irreversible myocardial injury 
compared to shorter periods (Tong et al. 2012).  Muir et al. (1967) reported that 
cardiac myocytes which underwent perfusion of zero Ca2+ for 30 minutes determined 
a clear separation of the fascia and macula adherence, while Ashraf (1979) observed 
similar changes in 10-15 minutes of exposure to the same environment.  
Perfusate pH and temperature: 
The severity of damage that occurs during Ca2+ paradox is suggested to be modulated 
by changes in pH of the perfusate. Gaintanaki et al (2002) reported that both lower 





of extracellular and intracellular hydrogen ion concentration hampers the massive 
Ca2+ influx by changing the cell membrane fluidity. 
 
Ca2+ paradox is also temperature-dependent, with nearly complete protection from 
Ca2+ paradox damage being afforded by a reduction of temperature at 18 ◦C or below 
(Rich and Langer 1982; Baker 1983). Hypothermia prevents the separation of the 
intercalated discs and detachment  of the glycocalyx (Baker 1983), and maintains the 
sarcolemmal permeability and preservation of sarcolemmal ultrastructural (Frank et 
al. 1982; Rich and Langer 1982). Ganote & Sims (1984) reported that hypothermia 
also prevents lysis of fascia adherence and therefore cytolysis. Furthermore, 
hypothermic Ca2+ free perfusion has been shown to prevent the depletion of 
myocardial Ca2 + (Alto and Dhalla 1979).  
 
The nature of electrolytes: 
The nature of electrolytes such as Ca2+, Na+ and other divalent cations may affect the 
degree of Ca2+ paradox injury. The magnitude of Ca2+ paradox injury is dependent 
upon the amount of Ca2+ present in the perfusion buffer during Ca2+ depletion and 
repletion. During Ca2+ depletion, trace amount of Ca2+ contaminates the Ca2+ free 
buffer enabled the recovery of contractile force completely upon Ca2+ repletion. Rich 
and Langer (1982), demonstrated that the separation of membrane super facial 
laminae after a period of  free Ca2+ perfusion of the rabbit intraventricular septum 
could be prevented if 50 µM Ca2+ contaminated the Ca2+- free buffer. During Ca2+ 
repletion, the most dramatic changes occur with high Ca2+ concentration in perfusate 
(Singal, Matsukubo, and Dralla 1979), most of recent studies used low Ca2+ 
concentration (< 2.5 mM) to minimize these changes (Xu et al. 2006; Zhang et al. 
2012). 
 
The amount of Na+ in the Ca2+- free and reperfusion media also has profound effects 
on Ca2+ paradox. Lowering of Na+ in the perfusion medium during Ca2+-free 
perfusion is protective against Ca2+  paradox damage (Reuter and Seitz 1968; Alto 





during Ca2+-free perfusion prevents marked increase in Na+ and when Ca2+ is 
reperfused, low intracellular Na+ prevents the Ca2+ overload (Reuter and Seitz 1968; 
Alto and Dhalla 1979). 
 
The presence of other divalent cations apart from Ca2+, such as barium, manganese, 
cobalt and Mg2+, also may modify the Ca2+ paradox by affecting the degree of 
cellular Ca2+ influx. Among these divalent cations, Mg2+ plays a key role in several 
important cellular functions related to Ca2+ channels in the heart and has been 
implicated in several cardioprotective conditions such as ischaemia reperfusion 
injury (I/R) (Mubagwa et al. 2007). Several mechanisms have been proposed as to 
Mg2+ might protect against I/R injury and include its anti-arrhythmic properties, 
inhibition of platelet aggregation, and increased energy production in the 
myocardium (Yusuf 1993; Chakraborti et al. 2002) as well as reduction of 
myocardial Ca2+ overload (Woods 1991). While the nature of the ultimate 
myocardial damage is similar for I/R and CP, the underlying mechanisms and the 
progression of the damage are different (Piper 2000), especially in that CP occurs 
even in absence of ischaemia (Zimmerrman and Hulsmann. 1966). 
 A key pathway for  cellular entry of both Mg2+ and Ca2+ into the cells is the newly-
identified Mg2+-sensitive ion channel called transient receptor potential protein 
melastatin (TRPM7) channels (Penner and Fleig 2007). TRPM7 channels are 





-sensitive cardiac (TRPM7) ion channels 
 
TRPM7 channel regulators: 
TRPM7 acts as a channel and at the same time as a kinase which is involved in 
regulating both cellular Mg2+and intracellular signaling pathways underlying cellular 
function (Penner and Fleig 2007). The TRPM7 kinase domain plays a structural role 
and has been proposed to be essential for ion channel activity. Kinase domain 





to Mg2+ (Schmitz et al. 2003). TRPM7 is inhibited by Mg2+, MgATP and other Mg2+ 
nucleotides (Nadler et al. 2001; Demeuse et al. 2006).When the cell has sufficient 
Mg2+, TRPM7 channels act as a negative signal to reduce further Mg2+ and Ca2+ 
uptake. In addition, TRPM7 channel activity, including in cardiac tissue, is regulated 
by extracellular pH (Gwanyanya et al. 2004). TRPM7 current activity in HEK-293 
cells was enhanced by decrease in  an extracellular pH (Li et al. 2007) and inhibited 
by acidic intracellular pH (Kozak et al. 2005). Physical factors (e.g., mechanical 
stretch) have also been reported to enhance TRPM7 channel activity (Oancea, Wolfe, 
and Clapham 2006; Tomohiro, Takahiro, and Yasunobu 2007). 
 
Extracellular TRPM7 inhibitors and modulators: 
Several modulators of TRPM7 channel activity have been studied such as 
extracellular Mg2+ (Su et al. 2010) as a voltage-dependent blocker and inhibitor of 
TRPM7 channels, 5-lipooxygenase inhibitors e.g., nordihydroguaiaretic acid 
(NDGA), AA861, and MK886 as potent blockers (Chen et al. 2010) and Ca2+ -
activated small conductance K+ channel blocker NS8593 (Chubanov et al. 2012). 
Other studies demonstrated that Waixenicin A potently and specifically blocks 
TRPM7 in a Mg2+-dependent manner (Zierler et al. 2011) and sphingosine, but not 
sphingosine-1-phosphate (S1P), is a potent inhibitor of TRPM7. The sphingosine 
analogue, fingolimod (FTY720) inhibits TRPM7 with similar potency to sphingosine 




TRPM7 may play a role in a range of pathophysiological processes, including 
neurological and CVDs. Functionally, TRPM7 is essential for cell survival and is 
involved in the regulation of cell adhesion (Su et al. 2006; Tong et al. 2012). 
Overexpression of TRPM7 in HEK-293 cells causes loss of cells attachment. The 
detachment of cells is proposed to be due to Ca2+-dependent protease (calpain) 
requiring TRPM7 activity by creating a high Ca2+ environment at the adhesion points 





(Zhang et al. 2012), the role of TRPM7 in Ca2+ paradox is still unknown. Also this 
study suggested that both Ca2+- and kinase-dependent mechanisms are involved in 
which overexpression of TRPM7 in cells causes increases of intracellular Ca2+ levels 
accompanied by kinase-independent cell spreading and formation of focal adhesions. 
A further role of TRPM7 in neuronal cells has been suggested by Aarts et al. (2003), 
who subjected cultured cortical neurons to prolonged oxygen and glucose 
deprivation (OGD), an experimental model of ischaemia which causes anoxic cell 
death. OGD caused significant influx of Ca2+ that correlated with the amount of cell 
death, but effects are unknown in cardiac cells.  
 
To further understand how TRPM7 channels are modulated and exert their potential 
physiological/pathological functions, we investigated the effect of TRPM7 inhibitors 






HYPOTHESIS AND AIMS 
 
Hypothesis 
We hypothesized that the cardiac injury induced by Ca2+ paradox (CP) phenomenon 
can be attenuated via the modulation of Ca2+ influx pathways by Mg2+ pretreatment 
or by the actions of inhibitors of the Ca2+-permeable Mg2+ sensitive (TRPM7) ion 
channels. 
 
Aims of the study 
1- To evaluate the effect of Mg2+ pretreatment on CP-induced myocardial injury. 
2- To investigate the effect of Mg 2+ sensitive ion channel (TRPM7) inhibitors on CP-


















MATERIAL AND METHODS 
 
Animals and animal care 
Adult male Wistar rats were used in this study (starting weights 250-300 g). Only 
males were used in the study as females undergo a hormonal cycle and can respond 
differently to acute myocardial injury compared to males (Vaccarino et al. 1995). 
The rats were obtained from the Stellenbosch University Research Animal Facility 
and transferred to the University of Cape Town Anatomy Building Animal Facility, 
where they were allowed to adapt to their new environment for two days before 
starting experimental procedures. The animals were kept in environmentally-
controlled rooms (12-hour light/dark cycle from 06:00 h to18:00 h; light intensity, 
150 Lux; temperature, 22 ± 1°C) and had free access to standard rat chow 
(Aquanutro, Cape Town, SA) and water.  
 
The experiments were approved by the Faculty of Health Sciences Animal Ethics 
Committee at the University of Cape Town (FHSAEC) (Protocol Ref AEC 014/014)  
(see Appendix VII) and were carried out in accordance with the Guidelines of the 
Care Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No.85-23, revised 1996). The animal experimental procedures 
performed were examined and authorised by South Africa Veterinary Council 
(SAVC). 
 
Drugs and Chemicals 
FTY720, NDGA, and the rest of the drugs and chemicals were also obtained from 
Sigma-Aldrich (Johannesburg, RSA). Sodium pentobarbitone was purchased from 







The first set of experiments (n=48) was designed to evaluate the effects of Mg2+ 
pretreatment on CP induced injury. For these tests, rats were divided into two groups 
as follows: 
1. Control group: rats were injected with saline (0.9% NaCl, i.p) once per day 
every morning for 7 consecutive days.  
2. Mg2+ pretreated group: rats were injected by MgSO4 (270 mg/kg body weight 
i.p) once per day every morning for 7 consecutive days. The dose of MgSO4 
was as per that used in other studies (Sameshima, Ota, and Ikenoue 1999).  
 
The second set of experiments (n=48) was designed to investigate the effects of 
TRPM7 inhibitors on CP-induced injury. For these experiments, rats were not 
pretreated with Mg2+. 
 
Heart isolation and perfusion technique 
Surgical procedures to extract rat hearts were performed under anaesthesia. The rats 
were anaesthetized with sodium pentobarbitone (70 mg/kg body weight, i.p.) and that 
was co-administered with heparin (500 I.U/kg body weight, i.p.) to reduce the risk of 
thrombus formation within the coronary vasculature or ventricular chambers. The 
depth of anaesthesia was assessed by loss of the pedal withdrawal reflex. 
Thoracotomy was performed by making an incision at xyphoid sternum to the lateral 
end of left and right costal margin. The incision was continued through the ribs, and 
the anterior chest wall was deflected upwards to expose the heart and pericardium. 
The heart was quickly removed and transferred into cold (4°C) modified Krebs-
Henseleit bicarbonate solution (K-H) in order to rinse it of blood, temporarily stop its 
beating, and preserve it from ischemic injury prior to perfusion. As a further step to 
minimise ischaemic injury before perfusion, the time between harvesting the heart 
and being completely perfused with  K-H buffer was kept under 3 min (Awan et al. 
1999). The aorta was cannulated with a stainless steel cannula and the hearts were 





 The perfusion K-H solution contains (in millimoles per liter), NaCl 118.5, KCl 4.7, 
CaCl2 1.8, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2 and glucose 11. K-H was filtered 
(7  pore size, Whatman filter paper, Sigma.SA) before use to remove particulate 
contaminants. CaCl2 was added after pH correction to avoid the precipitation of Ca2+ 
and phosphate in alkaline conditions (see Appendix I).  The K-H solution was 
continuously gassed  with 95% O2 plus 5% CO2 (pH 7.4 at 37◦C) (Bell, Mocanu, and 
Yellon 2011). A constant perfusion pressure was achieved by maintaining a constant 
hydrostatic pressure through positioning a reservoir at a known height above the tip 
of the perfusion cannula. All parts of the perfusion system were water jacketed and 
the temperature was adjusted to 37°C. 
 
At the end of perfusion experiments, hearts were wrapped in generic cling wrap to 
avoid freeze-drying related damage of the epicardium and then  stored at -20°C for 
TTC staining and analysis.  
 
Exclusion criteria 
In this study, no animals were excluded prior to the time of heart extraction. The 
exclusion criteria were applied to isolated hearts during the Langendorff perfusion 
and were formulated to ensure that the hearts were being adequately perfused during 
the stabilization period before the test protocol was started. For the protocol of 7 days 
treatment with saline or Mg2+, no animals were excluded during the treatment phase 
prior to killing the rats. The exclusion criteria were applied on perfused heart on 
Langendorff system where the bradycardiac (HR < 200 bpm), hypotensive (LVDP < 
60 mmHg) hearts and hearts with persistent non-sinus rhythm or severe ventricular 










Induction of CP: 
After 25 minutes of stabilization, CP was induced by 3 min perfusion with Ca2+-free 
K-H solution (Tong et al. 2012; Bi et al. 2012),  enriched with 0.1 mmol/l  EGTA in 
order to chelate Ca2+, followed by 30 min perfusion with a normal Ca2+-containing 
K-H solution. The Ca2+-free KH solution was perfused through a separate 
Langendorff fluid column, which converged with the main perfusion system at the 
common outlet (Fig 2). Preliminary tests were performed in order to optimize the CP 
protocol where the hearts perfused for 3, 5 or 10 mins with Ca2+ free solution (see 
example in Appendix II). 
 
 










TRPM7 inhibitors (1µmol/L FTY720 or 10µmol/L NDGA) were perfused for 5 min 
post stabilization followed by induction of CP (Fig 4). Doses of FTY720  and NDGA 
were chosen to achieve TRPM7 channel inhibition based on previous reports (Chen 
et al. 2010; Qin et al. 2013). Both drugs were dissolved in DMSO and further diluted 
in K-H buffer; final concentration of DMSO was 0. 01%. Both drugs were then 
delivered into an infusion port directly above the aortic cannula by an infusion pump 
(Graseby 2100, Medical Smith, SA). The infusion speed was adjusted according to 




For Mg2+ experiment, hearts were divided into four groups according to the 
pretreatment and perfusion protocol as follows (Fig 3): 
a) Mg2+: Hearts of rats pretreated with Mg2+ were perfused with normal KH 
solution throughout the perfusion duration. 
b) Mg2++CP:  Hearts of rats pretreated with Mg2+ were perfused for 25 
minutes stabilization followed by induction of CP. 
c) Control: Hearts of rats pretreated with saline were perfused with normal 
KH solution throughout the perfusion duration 
d) CP: Hearts of rats pretreated with saline were perfused for 25 minutes 
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Figure 3: Experimental protocol for isolated rat heart to investigate the effects of Mg
2+
 
pretreatment on CP-injury. 
For experiments involving TRPM7 inhibitors (FTY720 and NDGA), hearts were 
divided into six groups according to the drug treatment and perfusion protocol as 
follows (Fig 4): 
a) Control:  Hearts were perfused with vehicle (DMSO) for 5 min post 
stabilization followed by 33 min perfusion with normal K-H solution.   
b) FTY720:  Hearts were perfused with FTY720 for 5 min post stabilization 
followed by 33 min perfusion with normal K-H solution. 
c) NDGA:  Hearts were perfused with NDGA for 5 min post stabilization 
followed by 33 min perfusion with normal K-H solution. 
d) CP: Hearts were perfused with vehicle (DMSO) for 5 min post 
stabilization followed by induction of CP.  
e) FTY720 + CP: Hearts were perfused with FTY720 for 5 min post 
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f) NDGA + CP: Hearts were perfused with NDGA for 5 min post 
stabilization followed by induction of CP.  
 
20 mint                        5min         3min              30 min 
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Figure 4: Experimental protocol for isolated rat heart to investigate the effects of 
TRPM7 inhibitors (FTY720 and NDGA) on CP.  
 
Haemodynamics parameters 
After few minutes of perfusion, an intraventricular balloon was introduced into the 
left ventricle through the mitral valve. The balloon was custom-made from an 
ultrathin, compliant plastic wrapping film. The balloon was connected to a calibrated   
BP transducer (MLT0670, AD Instruments, Aus) that was coupled to a PowerLab 
data-acquisition system (AD Instruments, Aus). The balloon was filled with water 
and the volume of the balloon was gradually increased to a left ventricular (LV) end 
diastolic pressure (LVEDP) of 5-10 mmHg. Hemodynamic parameters measured 
from the BP transducer were recorded onto the computer via a Bridge Amplifier 
(ML221, AD Instruments, Aus) and were analysed with the LabChart Pro software 
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(AD Instruments, Aus) using the BP Analysis Module (see appendix III). LV systolic 
and LVEDP were obtained and left ventricular developed pressure (LVDP) was 
calculated as the difference between these values. The magnitude of left ventricular 
pressure was expressed as absolute value (mmHg) (see appendix). 
 
The coronary flow rate (CFR) was measured the effluent volume by collecting of the 
effluent draining from the apex of the heart over a fixed time (1 minute). 
Cardiac tissue damage evaluation  
Myocardial oxygen consumption rate:  
A dissolved O2 meter (PDO-520, S.A) was used to measure the O2 concentration in 
K.H solution and in the coronary effluent. The myocardial oxygen consumption rate 
(MVO2) was calculated according to equation (Romano et al. 2004) based on Fick`s 
principles as follows:  
MVO2 = [(PaO2 _ PvO2)  (c/760)]    
 
 In the equation, CF is coronary flow (ml/min); (PaO2 _ PvO2) is the difference in the 
partial pressure of oxygen (PO2, mmHg) between perfusate (a) and coronary effluent 
(v); and (c) is the Bunsen solubility coefficient of O2 in perfusate at 37°C, and 760 is 
the barometric pressure at sea level. The dissolved O2 meter automatically computes 
the value c/760. The setup and calibration of dissolved O2 meter is shown in 
Appendix IV.  
 
Infarct size:  
At the end of experimental protocol, the heart was decannulated and frozen at -20◦C. 
Once frozen, the heart was sectioned with a slice thickness of 2 mm perpendicular to 
the long axis and incubated for 20 minutes in 1% triphenyltetrazolium (TTC) in 
phosphate buffer (pH 7.4) at 37◦C.To remove excess TTC staining from non-viable 
tissue and for clear demarcation between the viable (red) and nonviable (pale) tissue, 
the stained myocardium was placed overnight in 10% formalin. The heart slices were 





scanned on a flatbed scanner. Infarct size was quantified with computerized 
planimetry Image J software (Image J, NIH Image). The area of viable and nonviable 
tissue was calculated and the infarct size was expressed as a percentage of the area at 





Blood was also collected at the time of exsanguination and plasma was obtained by 
centrifuging the blood at 2000g for 15 mins (Eppendorf Geratebau, Netheler Hinz, 
DEU). The plasma ionised Mg2+ level was analysed using automated photometric 
tests (Beckman AU, Path Care, SA). 
 
Statistical analysis 
In this study, data was presented as mean ± S.E.M. n indicated the number of rats 
studied under specific conditions. Data from multiple groups was compared using 
one-way analysis of variance (ANOVA), followed by post-hoc Tukey test where 
appropriate. For comparisons between two different groups, a non-paired t-test was 
used. The statistical analysis was performed by using Statistica programme (version 








 pretreatment on hearts subjected to CP: 
In Mg2+ pretreated experiments, all rats remained stable and active, and no rats died. 
On day 8 plasma, Mg2+ concentrations, measured 24 h after the final MgSO4 or 
equivalent saline injection (n=6), were not significantly different among the 
treatment groups (plasma Mg2+ in mmol/L 0.91 ± 0.05 mmol/L for  control group 
and 0.95 ± 0.04 mmol/L for the Mg2+ treated group (p = 0.62). 
Infarct size 
Control hearts had a baseline non-viable myocardium of 7 ± 1 % (Fig 5). CP 
significantly increased infarct size (50 ± 4 % vs. control; p < 0.001). Mg2+ 
pretreatment did not significantly improve infarct size during CP (50 ± 5% vs. CP; 
p = 1). Mg2+ treated hearts without CP displayed a baseline myocardial injury of 
7.0 ± 0.4% (p = 0.9 vs. control).  
 
Figure 5: Effects of Mg
2+
 pretreatment on the survival of heart tissue after CP.  
A. Representative cardiac tissue slice stained with TTC. B. Group results on the 
myocardial injury area, which was expressed as a percentage of the total area, n = 6-11, 






Haemodynamic parameters  
Control hearts had a pre CP LVDP of 71.83 ± 10.56 mmHg and LVEDP of 
15.40 ± 3.45 mmHg (Fig 6 and Fig 7). CP caused a significant decrease in LVDP 
(1.65 ± 1.60 mmHg vs. control; p = 0.001) and increased LVEDP (40.50 ± 
4.97mmHg vs. control; P = 0.039). Mg2+ pretreatment elicited no recovery of LVDP 
(5.9 ± 2.7 mmHg vs CP; p = 0.9) and LVEDP (43.8 ± 7.7 mmHg vs. CP; p = 0.9). At 
the end of perfusion, haemodynamic parameters were recorded for both Mg2+ treated 
and untreated. Pretreatment with Mg2+ had no effect on LVDP of 77.7 ± 19.5 mmHg 
(p = 0.9 vs. control) and LVEDP of 14.5 ± 4.6 mmHg (p = 0.9 vs. control) compared 
to control.  
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Figure 6: Representative typical left ventricular pressure (LVP) tracing for Mg
2+
 un 
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There was a tendency for CP to decrease CFR, but the CFR was not significantly 
different from control (P = 0.1 vs control) (Fig 8). Pretreatment with Mg2+ did not 
significantly alter post CP CFR (p = 0.9 vs CP). In addition, Mg2+ pretreatment alone 
did not alter CFR compared to control (p = 0.4 vs control). 
A) 
B) 
Figure 7: Effects of Mg
2+
 pretreatment on haemodynamic parameters.  
A. Left ventricular (LV) developed pressure (LVDP). B. LV end-diastolic 
pressure (LVEDP) for hearts subjected to CP. n = 6-11, * P ≤ 0.05, ** P ≤ 0.01 





Myocardial oxygen consumption rate (MVO2) 
Control hearts consumed O2 at a rate of 202 ±19 mg/min (Fig 9). CP caused a 
significant decreased in MV O2 (99 ± 17 mg/min vs. control; p = 0.01). Mg2+ 
pretreatment elicited no improvement of O2 consumption (134 ± 16 mg/min vs CP; p 
= 0.48). Pretreatment with Mg2+ had an MVO2 of 204 ± 20 mg/min, which was not 
significantly different from control (p = 0.9 vs. control).  
 
Figure 9: Effects of Mg
2+
 pretreatment on myocardial consumption rate (MVO2) after 
CP. n = 6-7, ** P ≤ 0. 01 (CP vs control), # P ≤ 0.05 (Mg2+CP vs Mg2+). 
Figure 8: Effects of Mg
2+
 pretreatment on coronary flow rate CFR) for hearts 









Control hearts had an infarct of 13.6 ± 0.7%  (Fig 10). CP caused a significant 
increase in infarct size (69.0 ± 6.2% vs. control; p < 0.001). FTY720, but not NDGA 
partially reversed this injury (36.0 ± 5.4% vs. CP; p < 0.001). NDGA treated hearts 
displayed an infarct of 13.7 ± 0.6% (p = 1 vs. control) and FTY720 hearts displayed 
an infarct of 13.3 ± 0.6% (p = 1 vs. control)   
 
 
Figure 10: Effects of TRPM7 inhibitors (FTY720 and NDGA) on survival of heart 
tissue. A. Representative images of mid-ventricular heart slices stained with TTC. B. Group 
results on the myocardial injury area, which is expressed as a percentage of the total area, 
n = 6-7, ***P <0.001 (CP vs control), ##P < 0.001 (NDGA+ CP vs NDGA), ††P< 0.01 (FTY+ 







Figure 11. Effects of TRPM7 inhibitors (FTY720 and NDGA) on haemodynamic 
parameters for hearts subjected to CP.  A. LVDP, B. LVEDP. n = 6-7, ***P <0.001 (CP 
vs control),  ##P < 0.01, ###P < 0.001 (NDGA + CP vs NDGA), ‡P < 0.05 (NDGA + CP vs 
CP), ¤P ≤ 0.05, ¤¤P < 0. 01 (FTY7 + CP vs CP).  
Haemodynamics parameters 
Control hearts had a post perfusion LVDP of 78.4 ± 14.8 mmHg and a LVEDP of 
18.6 ± 2.3 mmHg (Fig 11). CP caused a significant decrease in LVDP (0 mmHg vs. 
control; p = 0.0003) and an increase in LVEDP (70.6 ± 4.6 mmHg vs. control; 


























FTY720, but not NDGA, partially reversed the CP-induced injury by improving the 
LVDP (50.6 ± 14.9 mmHg vs. CP; p = 0.03) and deceasing in LVEDP (44.6 ± 6.7 
mmHg vs. CP; P = 0.003). In FTY 720-treated hearts without CP, the LVDP of 66.9 
± 17.6 mmHg was not significantly different from control (p = 0.9 vs. control), 
whereas the LVEDP of 43.7 ± 2.9 mmHg was higher than control (p = 0.003 vs. 
control). For NDGA-treated hearts, the LVDP of 67.7 ± 5.1 (p = 0.9 vs. control) and 
LVEDP of 31.8 ± 2.7 mmHg (p = 0.2 vs control) were not significantly different 
from control. 
 
Although, CP tended to decrease CFR, the CFR was not significantly different from 
control (P = 0.4 vs control) (Fig 12). In addition, treatment with FTY720 or NDGA 
did not significantly affect CFR compared to control or CP (p > 0.05, for FTY or 
NDGA vs. CP or control). 
 
 
Figure 12: Effects of TRPM7 inhibitors (FTY720 and NDGA) on the coronary flow rate 






Oxygen consumption rate (MVO2) 
Control hearts consumed O2 at a rate of 127.1 ± 13.4 mg/min (Fig 13). CP caused a 
significant decreased in oxygen consumption rate (81.2 ± 9.8 mg/min vs. control; 
p = 0.04). FTY720 (108 ± 8.3 mg/min) and NDGA (104.9 ± 7.8 mg/min) tended to 
reverse CP-induced injury by improving the MVO2 but without statistically 
significant differences compared to CP (p = 0.5). NDGA treated hearts had a MVO2 
of 126.7 ± 5.7 mg/min (p = 1 vs. control) and FTY720 had of 123.0 ± 14.8 mg/min 
(p = 0.9 vs. control). 
 
 
Figure 13: Effects of TRPM7 inhibitors (FTY720 and NDGA) on myocardial oxygen 











The present study has shown that Ca2+ paradox (CP) caused dramatic myocardial 
damage and depression in mechanical function as was reflected by the induction of 
infarcts, increased LVEDP, decreased LVDP as well as decreased CFR and MVO2. 
FTY720 partially reversed CP-induced injury by decreasing the infarct size and 
improving the haemodynamic function without significantly affecting CFR and 
MVO2. However, neither pretreatment with Mg²⁺ nor application of NDGA reversed 




pre-treatment on CP-induced myocardial injury 
Mg2+ is one of the most plentiful cations in living cells and it plays an important role 
in regulation of various biological activities (Chakraborti et al. 2002). Clinically, the 
application of Mg2+ remains controversial in myocardial protection. Two major 
clinical studies, the Second Leicester Intravenous Mg2+ Intervention Trial (LIMIT- 2, 
1992) and the Fourth International Study of Infarct Survival (ISIS-4, 1996) provide 
conflicting evidence for the role of Mg²⁺ as a cardioprotective agent. Despite these 
conflicting results, several previous reports of experimental myocardial infarction 
have suggested that Mg²⁺ treatment should be effective in reducing ventricular 
arrhythmias and infarct size (Matsusaka et al. 2002). However, most of the studies on 
the protective effects of Mg2+ have been done in I/R experiments, and less is known 
about CP.  
 
In the current study, Mg²⁺ pretreatment did not reverse CP-induced myocardial 
injury. The lack of Mg2+ protection in CP is in contrast to findings of (Rich and 
Langer 1982) who reported  that  even 50 µM of Mg2+ during the Ca2+-free period 
exhibited ability to protect when Ca2+ was reperfused in isolated interventricular 
rabbit septum. The mechanism proposed in that study was that Mg2+ substituted Ca2+ 
at sarcolemmal binding sites to preserve control of Ca2+ permeability during the Ca2+ 





Mg2+ in that study compared to pretreatment in our protocol, different species used, 
and the use of a whole organ model. 
 
There are several possible reasons why Mg2+ may not have shown protection against 
CP. There are also possibly two concurrent opposing effects of Mg2+ on CP; the 
protective action via prevention of Ca2+ overload and the detrimental activation of 
the proteinase calpain. In the cardiovascular system, Mg2+ frequently modulates the 
cytosolic concentration of Ca2+ through the Ca²⁺-permeable channels (Saris et al., 
2000). Meissner and Henderson (1987) have demonstrated that Mg2+ modulates Ca2+ 
release from cardiac SR vesicles and reduce mitochondrial Ca2+ overload. Mg2+ as a 
physiological Ca2+ blocker also competes with Ca2+ for binding to troponin C and 
prevents or significantly reduces Ca2+ influx into the cell, since Ca²⁺-permeable 
channels can be inhibited by the presence of extracellular Mg2+ (Meissner and 
Henderson 1987). Since Ca2+ overload has an important role in the pathogenesis of 
Ca2+-paradox injury, the Ca2+ channel blocking properties of Mg2+ may be expected 
to be cardioprotective. While the above-mentioned prevention Ca2+ overload by Mg2+ 
can be protective, there is also the possibility of opposing effects via the activation of 
calpain by Mg2+. The activation of calpain is critical event that leads to tissue death 
in the CP (Su et al., 2006; Zhang et al., 2012). Mg2+ is known to activate calpain (Su 
et al. 2006; Su et al. 2010), and therefore may be expected to cause myocardial 
damage. Such an effect may have countered any direct protective effects Mg2+ might 
have. 
Some studies showed that the timing of Mg2+ administration is critical (Seelig and 
Elin 1996), but these studies were performed on I/R rather than CP. Clinically, when 
the Mg2+ is given to patients after acute MI, it reverses the arrhythmias and improves 
the regional myocardial blood flow by vasodilatation of systemic vasculature and 
coronary arteries and by platelets inhibition (Woods 1991). In I/R experimental 
animals, when the Mg2+ plasma concentration is increased before the onset of 
myocardial injury, the development of necrosis may be slow; adjunctive Mg2+ 
treatment given with early reperfusion may further limit infarct size (Hearse et al., 
1978). In addition, Mg2+ infusion is effective as adjunct therapy to enhance 
myocardial salvage in acute myocardial infarction. However, its effectiveness may 





combined with early reperfusion therapy (Leor and Kloner 1995). However, in our 
study, Mg2+ was administrated for 7 consecutive days before the day of experiments 
prior to CP and the level of plasma Mg2+ in the rats treated with Mg2+ was not 
different from control rats. Therefore, possibly the normal level of circulating Mg2+ 
at 24 hours after the last Mg2+ dose may be due to the kidneys having already 
excreted the excess Mg2+. However, the dose of Mg2+ that was used in this study was 
still expected to reach therapeutic level at the time of injection as shown in other 
studies where similar doses of Mg2+ were used (Sameshima, Ota, and Ikenoue 1999). 
  
 
Effects of TRPM7 inhibitors on CP-induced myocardial injury 
Another key finding in the present study was that FTY720, but not NDGA, was 
partially effective at rescuing heart contractile dysfunction and tissue death from CP-
induced injury as well as reduced the extent of ischaemic contractures as was 
indicated by decreased LVEDP. This finding of FTY720 protection in CP is novel 
since there were no previous studies which explored the effects of FTY720 on CP. 
FTY720 has demonstrated a protective effect in prevention of I/R injury in an animal 
model (Kaudel et al. 2007). The underlying mechanisms for their cardioprotective 
effects in this study or other studies remain poorly understood. The effects of 
FTY720 on contractile function and myocardial tissue viability might result from the 
activation of S1P receptor- dependent or –independent mechanisms. Some studies 
suggests that the activation of Akt underlies the protective effects of FTY720 
treatment after myocardial I/R (Hofmann et al. 2009). Egom et al. (2010) and Egom 
et al. (2011) reported that, FTY720 effectively antagonizes both bradyarrhythmias 
and tachyarrhythmias induced by I/R injury via activation of p21-activated kinase 
(Pak1)/AKT signaling.  In vivo, FTY720 administered might behave in a dual 
manner by both S1P-like effects and sphingosine-like effects (Vessey et al. 2013). 
FTY720 may also act through S1P independent mechanisms (X Qin et al. 2013) by 
inhibition of TRPM7 channel activity by masking negative charges of PIP2 and by 
blocking endogenous TRPM7 currents (Qin et al. 2013). In the present study, it is 







Despite the infarct size reduction by FTY720, we noticed that under control 
conditions, it significantly increased the LVEDP at the end of perfusion compared to 
control hearts. The reason for this effect is not clear, but some studies have shown an 
increase in mean arterial pressure in conscious rodents during FTY720 infusion  
Fryer et al. (2012) reported that FTY720 elicited dose-dependent hypertension after 
multiple days of oral administration in rat (Forrest et al. 2004). In contrast, small and 
transient decreases in mean arterial pressure have been reported for FTY720 in 
healthy human subjects (Schmouder et al. 2006).  
 
 
Although NDGA also inhibits TRPM7 channels (Chen et al. 2010), NDGA failed to 
decrease the level of LVEDP and preserve myocardial tissue against CP. Overall, the 
lack of protection by NDGA as a TRPM7 channel blocker and by Mg2+ as a TRPM7 
channel inhibitor, suggested that the FTY720 protection seems to be not related to its 
modulation of TRPM7 channels. Despite this lack of modulation, the role of TRPM7 
in CP is still unknown, given that the dose of inhibitors selected to block TRPM7 
channels in isolated cells. FTY720 (Chen et al. 2010; Qin et al. 2013).  Su et al. 
(2006) reported that overexpression of TRPM7 in HEK-293 cells caused loss of cells 
attachment. The detachment of cells is proposed to be due to Ca2+-dependent 
protease (calpain) requiring TRPM7 activity by creating a high Ca2+ environment at 
the adhesion points. In addition, TRPM7 overexpression causes oxidative and 
nitrosative stresses, producing cell rounding mediated by p38 MAPK/JNK-dependent 
activation of  calpain (Su et al. 2010).  
 
NDGA is a selective inhibitor of  arachidonic acid 5-lipoxygenase activity, which 
reduces leukotriene and prostaglandin synthesis leading to a reduction of 
inflammatory pathways (Lü et al. 2010). Chen et al.( 2010) reported that treatment of 
cells with NDGA reduces cell death caused by apoptotic stimuli. In contrast, 
Starkopf et al. (1998) reported that hearts pretreated with NDGA and subjected to 
regional ischaemia demonstrated  poor recovery of contractile function with high 
levels of end diastolic pressure after reperfusion. Furthermore, Murphy et al. (1995) 
reported that NDGA blocked the protective effects of preconditioning on post-
ischaemic contractile dysfunction in the isolated perfused rat heart. NDGA also 
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partially blocked the ability of preconditioning to attenuate the rise in cytosolic free 
Ca2+ during sustained ischaemia. 
Under control conditions, the application of NDGA had no significant effects on 
haemodynamic as well as on infarct size at the end of perfusion. These results were 
in agreement with those of Murphy et al (1995) who reported that 30 minutes of 
perfusion with NDGA did not significantly change LVDP or the CFR.   
Limitations of the study 
One of the major limitations of this study is the clinical relevance of the CP. The CP 
cardiac injury represents a severe model due to complete removal of Ca2+ with the 
addition of EGTA as a Ca2+ chelator. Such conditions are not physiological because 
even 50 µM of Ca2+ in K-H buffer has been shown to protect against CP injury (Rich 
and Langer 1982). Therefore, the conditions where extracellular Ca2+ is completely 
depleted are not expected to occur under most clinical conditions. However, it is 
possible that there may be various degrees of myocardial damage proportional to the 
degree of Ca2+ depletion under physiological conditions. This possibility partly 
accounts for why CP has become an important experimental model for studying the 
basis of myocardial injury associated with Ca2+ abnormalities and has been studied in 
the heart of various mammalian species as well as in isolated cardiomyocytes.    
Another limitation in this study especially for the Mg2+ pretreatment experiment is 
that the Mg2+ tissue levels were not determined. While, the Mg2+ dose used in this 
study is expected adequate to reach therapeutic level (Sameshima, Ota, and Ikenoue 
1999), some cellular changes are expected to occur even if plasma Mg2+ level is not 
different between Mg2+-treated and control groups (Amoni et al. 2016). To clarify 
the issue of Mg2+ bioavailability, it would be necessary to measure the Mg2+ at tissue 
or cellular levels, but due to unavailability of equipment and time constraints, these 
parameters were not assessed in the current study. 
In general, the Langendorff preparation and the isolation of the hearts from the whole 
animal are artificial processes that take studies further away from clinical relevance. 





contractile function (Bell, Mocanu, and Yellon 2011). Furthermore, the artificial K-H 
buffer used as perfusate has limited oxygen-carrying capacity of crystalline solution, 
and has low oncotic pressure compared to blood.   
 
Future perspectives  
In order to elucidate the role of FTY720 in cardioprotection against CP, further 
studies are required to clarify the exact mechanisms underlying the protection of 
FTY720 in CP.  It would be important to employ different models with or without 
the use of direct pharmacological blockade such as VPC 23019 (a competitive 
antagonist of S1P receptors type 1 and 3). 
 
It would also be of interest to repeat our experiments using an in vivo rather than an 
isolated heart model, which include the systemic effects of FTY720 and allow 
examining the long term effects of FTY720 on the myocardium. Many studies have 
been done on TRPM7 channel expression and its role in regulation of Ca2+ and Mg2+ 
(Montell 2003; Fleig and Penner 2004), but there are no studies that evaluate TRPM7 
expression in the heart and the effect of FTY720 application on it. So, it would be 
important to do western blot analysis to investigate the effect of FTY720 application 
on TRPM7 expression in the heart. 
 
Conclusion   
In this study, the results showed that FTY720 application, but not NDGA application 
or Mg2+ pretreatment, partially reversed the CP-induced injury by decreasing the 
infarct size and improving the haemodynamic function, without effect on CFR. The 
mechanisms underlying the FTY720 cardioprotection seems to be not related to its 
modulation of TRPM7 channels, given the lack of protection by neither Mg2+ 
pretreatment nor NDGA.  Although, Mg²⁺ did not reverse CP-induced injury as 
would have been expected via Ca2+- blocking effects, Mg²⁺ still has a place in 
cardiovascular medicine as an essential nutrient and a deficiency creates adverse 
effects on physiological functioning. The clinical implication of these results is that 
there is a potential for the clinical uses of FTY720 to be extended to provide 
cardioprotection in conditions of CP. However, it is still not clear if the sphingosine 
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1-phosphate receptor-mediated mechanisms that are common to the actions of
several sphingolipids like FTY720 are involved in this cardioprotection. Further
studies are required to clarify the exact mechanisms underlying the cardioprotection
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I- Krebs- Henseleit buffer for Langendorff perfusion (3L)
NaCl  20.775g 
 KCl        1.051g  
NaHCO3  6.301g 
MgSO4.7H2O  0.433g 
KH2 PO4        0.490g 
 Glucose         5.945g 
CaCl2.2H2O  0.599g 
EGTA         0.095g 
II- Preliminary data
For optimization of Ca2+ paradox protocol, some preliminary experiments were done 
to demonstrate the perfusion-protocol conditions and duration where the hearts 







III- BP Settings in BP Analysis Module of Lab Chart  
 
 
The analysis type was selected for ventricular BP. The cycle detection was set at 20 











IV- Dissolved oxygen meter
Before the measurement, the meter should be processed the following. 
Probe maintenance: 
1- Unscrew the probe head.
2- Fill the electrolyte into the container of the probe head.
3- Screw the probe head into the probe body.
Calibration procedures:
1- Connect the oxygen probe plug into the Input Socket.
2- Power on the instrument by pushing the power Off/On button. The display
will show the O2% and the temperature values. Wait for 3 minutes at least
until the display reading values become stable and no fluctuation.
3- Press the HOLD button once, the display will show the hold indicator, then
following press the REC button once, the display will show the text CAL that
will flash, then the upper value will count down from 30 to 0 then the display
will show the values exactly same as 20.9 or 20.8 (As the oxygen in the air is
20.9% typically, so use the environment air O2 value for quick and precise
calibration).
Measurement: 
1- In order to measure the dissolved oxygen content in a liquid, it is





probe to make sure that velocity of liquid coming into contact with the 
probe.  
2- For changing  the unite from % O2 change to mg/L, press the Hold button 
continuously at least two seconds, the display indicator will change.  
V- TTC Stain from Defrosted Heart Sections 
Recipe for TTC Buffer Solution A 
 
100 M Monobasic sodium (acidic phosphate) 15.6 g  
Distilled water 1000 ml 
Recipe for TTC Buffer Solution B 
100 M Dibasic sodium (alkaline phosphate) 14.2 g 
Distilled water 1000 ml 
Recipe for 1% TTC Solution 
Mix 4 parts solution B: 1 part solution A and titrate to pH 7.4 
Add 250 mg TTC in 25ml buffer solution 
TTC stain was conducted using the standard protocol. 
VI- Infarct Size Quantification with ImageJ 
File           Open          Scan picture (view one heart with one side at a time)         
Zoom to accurate viewing then Select polygon icon            Hold shift and click along 
outline of heart slice            Release shift            Measure the entire area            Edit           
Clear outside           Image            Colour               Split channels              Close other 
windows and only use the “green” channel Image              adjust              threshold 
(The grey is the infarcted area, but with ImageJ this cannot be measured so there is a 
need to measure the red area and minus it from the total in an excel worksheet). 
Hold shift and click red part of the slices making sure to not include the white cut out 
areas (ventricles etc) or the grey infarcted area            measure      
Open excel worksheet and input values from measure panel in Image J. 
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